NCT00015756|Completed
Tissue Collection From People With Cystic Fibrosis
Tissue Collection Protocol for Individuals With Cystic Fibrosis
Loading search results
Tissue Collection Protocol for Individuals With Cystic Fibrosis
Sponsor study identifier
Secondary identifiers
observational
100
1 country
2
Study Start
May 2, 2001
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
April 21, 2008
Date type not reportedThis date has not been verified as actual or estimated.
This study will examine the relationship between bacterial products in lung infections in cystic fibrosis and disease severity. It will examine plasma and lung tissue from cystic fibrosis patients. Patients with cystic fibrosis and having certain genetic characteristics, who are between 9 and 65 years of age and any cystic fibrosis patient undergoing lung transplantation at INOVA Fairfax Hospital in Fairfax, Virginia, may be eligible for this study. Patients who cannot undergo apheresis may be asked to provide up to an additional 100 cc (7 tablespoons) of blood for research to look at bacterial products. Lung specimens of participating transplant patients will be collected at INOVA Fairfax Hospital. Patients who participate in the apheresis portion of the study will be admitted to the NIH Clinical Center for 2 to 3 days. Apheresis is a procedure for collecting large quantities of specific blood components. For this study, plasma-the liquid part of the blood-will be collected. For the procedure, whole blood is collected through a needle in an arm vein, similar to donating blood. The blood is separated into its components by centrifugation (spinning), the plasma and white cells are extracted and collected in a bag, and the red cells are returned to the body, either through the same needle or through another needle in the other arm. During the hospital stay, patients may also be asked to participate in other cystic fibrosis studies involving blood tests, an echocardiogram (ultrasound test of the heart), urine pregnancy test, and pulmonary function (breathing) tests.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
April 21, 2008
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2, 2001
Date type not reportedThis date has not been verified as actual or estimated.
May 4, 2001
Actual (reported)May 7, 2001
Actual (reported)April 21, 2008
Date type not reportedThis date has not been verified as actual or estimated.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, 20892, United States
Medical College of Wisconsin 8701 Watertown Plank Road Milwaukee, WI 53226
Milwaukee, Wisconsin, 53226, United States
Frank DW. The exoenzyme S regulon of Pseudomonas aeruginosa. Mol Microbiol. 1997 Nov;26(4):621-9. doi: 10.1046/j.1365-2958.1997.6251991.x.
First Submitted
May 4, 2001
First Posted
May 7, 2001
Study Start
May 2, 2001
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
April 21, 2008
Date type not reportedThis date has not been verified as actual or estimated.
Study of Hepatic Glucose Production and De Novo Lipogenesis in Patients With Cystic Fibrosis
Contact the study team to confirm eligibility.
Last Updated
July 2, 2017
Record last verified: 2008-04-21
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: